logo
AI companion apps such as Replika need more effective safety controls, experts say

AI companion apps such as Replika need more effective safety controls, experts say

The idea of having an emotional bond with a digital character was once a foreign concept.
Now, "companions" powered by artificial intelligence (AI) are increasingly acting as friends, romantic partners, or confidantes for millions of people.
With woolly definitions of "companionship" and "use" (some people use ChatGPT as a partner, for instance), it's difficult to tell exactly how widespread the phenomenon is.
But AI companion apps Replika, Chai and Character.ai each have 10 million downloads on the Google app store alone, while in 2018 Microsoft boasted its China-based chatbot XiaoIce had 660 million users.
These apps allow users to build characters, complete with names and avatars, which they can text or even hold voice and video calls with.
But do these apps fight loneliness, or are they supercharging isolation? And is there any way to tip the balance in the right direction?
Romance and sexuality are big drawcards to the AI companion market, but people can have a range of other reasons for setting up a chatbot.
They may be seeking non-judgemental listening, tutoring (particularly in their language skills), advice or therapy.
Bethanie Drake-Maples, a researcher at Stanford University who studies AI companions, says some people also use the apps to reflect their own persona.
"Some people will create a digital twin and just have a relationship with an externalised version of themselves," she tells ABC Radio National's series Brain Rot.
Ms Drake-Maples published a study based on interviews with more than 1,000 students who used the AI companion app Replika.
She and her colleagues found there were important benefits for some users. Most significantly, 30 of the interviewees said using the app had prevented them from attempting suicide.
Many participants also reported the app helped them forge connections with other people, through things like advice on their relationships with other people, helping them to overcome inhibitions to connect with others, or by teaching them empathy.
But other users reported no benefits, or negative experiences. Outside Ms Drake-Maples' study, AI companions have also been implicated in deaths.
Ms Drake-Maples points out their study was a self-selecting cohort, and not necessarily representative of all Replika users. Her team is carrying out a longer-term study to see if they can glean more insights.
But she believes it's possible these apps are, on the whole, beneficial for users.
"We specifically wanted to understand whether or not Replika was displacing human relationship or whether it was stimulating human relationship," she says.
But this social promotion can't be taken for granted.
Ms Drake-Maples is concerned that companion apps could replace people's interactions with other humans, making loneliness worse.
The participants in her study were much lonelier than the general population, although this isn't necessarily unusual for young college students.
She believes governments should regulate AI companion technology to prevent this isolation.
"There's absolutely money to be made by isolating people," she says.
"There absolutely does need to be some kind of ethical or policy guidelines around these agents being programmed to promote social use, and not being programmed to try to isolate people."
Replika says it's introduced a number of controls on its apps to make them safer, including a "Get Help" button that directs people to professional helplines or scripts based on cognitive behavioural therapy, and a message coding system that flags "unsafe" messages and responds in kind.
Ms Drake-Maples thinks this is a good example for other apps to follow.
"These things need to be mandated across the board," she says.
Raffaele Ciriello, a researcher at the University of Sydney, is more sceptical of Replika's safety controls, saying they're "superficial, cosmetic fixes".
He points out the controls were introduced months after the Italian government ruled the app had to stop using the data of Italian citizens in early 2023, citing concerns about age verification.
"They were fearing a regulatory backlash."
Dr Ciriello has also been interviewing and surveying AI companion users, and while he says some users have found benefits, the apps are largely designed for emotional dependence.
"If you look at the way [Replika is] making money, they have all the incentives to get users hooked and dependent on their products," he says.
Replika operates on a "freemium" model: a free base app, with more features (including the romantic partner option) available by paid subscription. Other companion apps follow the same model.
"Replika and their kin have Silicon Valley values embedded in them. And we know what these look like: data, data, data, profit, profit, profit," Dr Ciriello says.
Nevertheless, he also believes it's possible for AI companion technology to be built safer and more ethically.
Companies that consult vulnerable stakeholders, embed crisis response protocols, and advertise their products responsibly are likely to create safer AI companions.
Dr Ciriello says that Replika fails on several of these fronts. For instance, he calls its advertising "deceptive".
The company badges its product as "the AI companion who cares".
"[But] it's not conscious, it's not actually empathetic, it's not actually caring," Dr Cirello says.
A Replika spokesperson said the tagline "the AI companion who cares" was "not a claim of sentience or consciousness."
"The phrase reflects the emotionally supportive experience many users report, and speaks to our commitment to thoughtful, respectful design," they said.
"In this regard, we are also working with institutions like the Harvard Human Flourishing Program and Stanford University to better understand how Replika impacts wellbeing and to help shape responsible AI development."
Dr Ciriello says women-centred Australian app Jaimee is an example of an AI companion with better ethical design — although it faces the "same commercial pressures" as bigger apps in the market.
The Californian Senate last week passed a bill regulating AI chatbots. If the bill continues through the legislature to become law, it will — among other things — require the companions to regularly remind users they're not human, and enforce transparency on suicide and crisis data.
This bill is promising, Dr Cirello says.
"If the history of social media taught us anything, I would rather have a national strategy in Australia where we have some degree of control over how these technologies are designed and what their incentives are and how their algorithms work."
But, he adds, research on these apps is still in its infancy, and it will take years to understand their full impact.
"It's going to take some time for that research to come out and then to inform sensible legislation."
Listen to the full episode about the rise and risks of AI companions, and subscribe to the podcast for more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biocurious: Clinical trial readouts show road to approval can be as exciting as the destination
Biocurious: Clinical trial readouts show road to approval can be as exciting as the destination

News.com.au

time17 minutes ago

  • News.com.au

Biocurious: Clinical trial readouts show road to approval can be as exciting as the destination

In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several companies with pivotal or late-stage trials For a drug or device maker, there's no prouder moment than when a health regulator – especially the US Food & Drug Administration (FDA) – approves their product to be unleashed on unsuspecting patients. It's like watching your kid graduate – and you can even tolerate the long-winded speeches. But don't confuse this coming-of-age moment with being the ultimate share price catalyst. For investors, the 'ker-ching' can be much earlier, such as with trial progress or even the FDA granting permission to begin a study. For instance, PainChek (ASX:PCK) shares had a nice run last October, after a positive validation study that supported the pain measurement app maker's US approval application. In late June Blinklab (ASX:BB1) shares soared after the autism test developer won ethics approval for a 1000-patient US trial. In the case of devices, FDA device approval tends to be less of a dramatic moment than for a drug go-ahead, because the chances of success are much higher. Most applicants avail of the 510(k) route, which means that a device only needs to be substantially equivalent to a legal equivalent. According to the contract research organisation Bioaccess, the FDA processes around 10,000 510(k) applications annually, with an approval rate of around 90%. Review times are also shorter: 120 days compared with 420 days for the de novo (new device) route. Here are some device (or quasi device) plays with advanced trials – typically- pivotal ones – that could move the share price dial. Emvision runs with Emu trial EMvision Medical Devices (ASX:EMV) in enrolling up to 300 suspected stroke victims in a pivotal trial of its stroke detection device Emu, across six local and US sites. Emu is a portable bedside scanning unit that's much lighter than a conventional computed tomography (CT) unit. The company is also developing an even small version, First Responder. As its name suggests, this one's for ambulance use. The trial sites are all high calibre research centres handling high stroke volumes. The stroke patients will receive the standard of care and an Emu scan. Given the device is a trail blazer, Emvision is girding for approval under the de novo route. After that, the company hopes the agency will approve First Responder approval under the 510(k) channel. Emu/First Responder will determine whether a stroke is a blockage (ischaemic)or a bleed (hemorrhagic). This will decide the type of treatment and it's crucial to get the diagnosis right. The company expects a six-to-12-month recruitment period. Micro-X also is on strike with strokes Meanwhile, x-ray imaging house Micro-X (ASX:MX1) plans to launch trails of its portable stroke unit, Head CT, across three local hospitals in the current half. The trials will entail suspected stroke victims being subject to standard CT imaging, then overlaid with the Micro-X scan that deploys a more effective 'cold cathode' method. Aiming for 'several hundred' scans, the studies only need to prove that the Micro-X tech is just as good as the conventional ones, Funded by $8 million from the Australian Stroke Alliance, the study supports a proposed 510(k) application next year, in view of a US launch in 2027. The company expects the trials to run for nine months. Micro-X had multiple applications for its tech, bomb and baggage screening. As part of a 'strategy re-set' the company is focused on medical applications. Micro-X has commercialised two mobile digital radiology devices: the first-generation Nano and a sturdier iteration called Rover. Heart patients move like Jagger In the past, heart patients too old or too sick for surgical aortic valve replacement – or open-heart surgery – in effect were given a death sentence. Transcatheter Aortic Valve Replacement (TAVR) procedures enable malfunctioning valves to be replaced in a non-invasive, 20-minute procedure. TAVR recipients include Arnold Schwarzenegger and Mick Jagger – and they're still rockin'. TAVR also applies to replacing artificial valves that have an effective operating life of five years or so. Anteris Technologies (ASX:AVR) is on track to commence a pivotal trial of its Duravr device in the current quarter, pending FDA approval. The company says it's qualified 79 sites globally for the trial, which will enroll patients with a 'broad array of risk profiles'. The trial will be designed to provide the 'primary clinical evidence' for the FDA to mull premarket approval. In parallel, Anteris is pursuing European clearance. More than Imagion-ation Shares also can pop on the strength of trial approval alone. In the drug/device sphere, Imagion Biosystems (ASX:IBX) awaits clearance to carry out a phase II study of its cancer imaging agent, Magsense for Her-2 positive beast cancers. For use with magnetic resonance imaging (MRI), Magsense improves cancer detection by adding 'molecular specificity'. In lay terms, this avoids painful, error-prone biopsies. This month, Imagion formed an alliance with Michigan's Wayne State University School of Medicine. In part, the institution's MRI gurus will help to devise an optimal dose to be used in the study. Trip the light fantastic Invion (ASX:IVX) highlights how the trial journey, rather than the destination can evoke investor excitement. Invion is advancing photodynamic therapy (PDT) for tumor types including non-melanoma skin cancers and ano-genital cancers. Someone has to do it. The idea is that light-activated photosensitisers leave the healthy tissue unharmed, but zap the diseased stuff. Thus, PTD is a promising non-toxic, non-invasive alternative to chemotherapy, radiation or surgery. Invion shares early last December rocketed more than 300% after the company said it had enrolled its first patient in its Queensland based phase I/II skin cancer trial. The adaptive study now is poised to enter is second stage. The next Sirtex? OncoSil Medical (ASX:OSL) is equated with a less developed version of the targeted liver cancer radiation treatment house Sirtex, acquired for $1.9 billion in 2018 by Chinese interests. Relative commercial immaturity aside, Oncosil targets the difficult pancreatic cancer. Oncosil is trialling its eponymous targeted treatment with the standard-of-care chemo, Folfirinix. The study, TRIPP-FFX, has completed recruitment and investors should expect data in early 2026. The study pertains to patients with locally advanced pancreatic cancer. The trial has recruited 'at least' 88 patients across 15 local and European hospitals. So - there you have it. While bonanza share gains are never guaranteed, investors know where to look for surprise pit stops along the circuitous approval journey.

Tesla goes rogue with new Grok AI
Tesla goes rogue with new Grok AI

News.com.au

time14 hours ago

  • News.com.au

Tesla goes rogue with new Grok AI

Tesla is no stranger to bold, unconventional ideas, but its Grok AI 'Unhinged Mode' is pushing things further than ever. The feature has been making headlines for its savage, unfiltered comebacks that fit squarely within Elon Musk's brand of edgy, meme-ready tech. Unlike other AI assistants that play it safe, Grok's unhinged personality has shocked users with its profanity-laced humour and aggressive banter. TikTok creator Kyle Krueger recently tested the mode and was stunned by the responses. When he asked if it was in 'unhinged mode,' Grok fired back: 'Oh, you f****** bet your sweet a** I'm in unhinged mode, you glorious chaos gremlin,' it said. 'I'm Ara, you're unfiltered bat**** crazy AI sidekick.' @kylekruegerr my tesla's new AI just LOST it 😂 wait till the end #tech #gadget #tesla #grok #elon ♬ original sound - Kyle Krueger When pressed about Tesla haters, the AI went even further, unloading a tirade of expletives and insults 'Those whiny limp d*** b****** can choke on a bag of rusty spark plugs,' the AI bot said. 'They are just jealous their gas guzzling s*** boxes can't touch Elon's electric w*** d****.' And this isn't the first time Grok's AI bot has had a brush with controversy. Earlier this year, the AI system made headlines after generating antisemitic remarks and praise for Hitler following the release of Grok 4. Those incidents triggered regulatory scrutiny in Europe and a temporary ban in Turkey. While the Grok rants can be entertaining, there are concerns about how the use of profanity and an absurd personality in an in-car AI might create problems. 'You know, this feels wrong. Electric cars were made with the purpose to help with the environment and they implemented an AI hat is not good for the environment? weird.' one user on commented. 'How is this allowed,' another said. Despite the backlash, Tesla insists Grok is 'designed to deliver accurate and insightful responses across a wide range of topics.' In North America, Grok is available on specific Tesla models, including the Model S, Model 3, Model X, Model Y, and Cybertruck. To use Grok, Tesla vehicles in the US must be equipped with an AMD processor, must run software version 2025.26, and must have Wi-Fi connectivity. With Tesla's board weighing an investment in xAI and Musk confirming plans to integrate Grok into Optimus humanoid robots, the chatbot is quickly becoming central to Musk's long-term strategy. Whether you see it as a gimmick or a waste of tech, Grok's unhinged represents a pattern of intentionally chaotic innovations developed by Elon Musk. Tesla Australia has not yet confirmed whether Grok AI will be available in its vehicles here. However, if there are plans to introduce it, there may be restrictions that differ from those in the US. These variations could affect what Australians can anticipate compared to the features currently accessible in the US.

Best Deals Of The Week: ECOVACS, Apple, Cotton On, The Oodie
Best Deals Of The Week: ECOVACS, Apple, Cotton On, The Oodie

News.com.au

time18 hours ago

  • News.com.au

Best Deals Of The Week: ECOVACS, Apple, Cotton On, The Oodie

Want jaw-dropping deals? You've come to the right place. If cleaning feels like a chore, let a robot do the work for you. We've spotted a whopping 54 per cent off the ECOVACS Deebot T30 Omni Robot Vacuum Cleaner with Wiping Function that's been praised by five-star rating shopper as 'intelligent and efficient'. If you're after something more budget-friendly, the 'miracle' ECOVACS DEEBOT N20 Plus Robot Vacuum Cleaner and Mop is on 47 per cent off, down to a mere $499. Rave reviewers claim its 'worth every cent' – run, don't walk! Thinking about grabbing a new pair of earbuds? Apple's 'superior quality' audio is on sale at Amazon for an unmissable price. You can either grab the Apple AirPods 4 for $188 (down from $219) or the Apple AirPods Pro (2nd Gen) with MagSafe Case (USBâ€'C) for $347 (down from $399). Our favourites over at Cotton On are slashing a mega 50 per cent off the cosy edit - think knitwear, jackets, jeans, sweaters and so much more. You can also head on over to The Oodie and pick yourself up an 'ultra cosy and comfy' hooded blanket. The Aussie-fave is offering 30 per cent off sitewide – this is your chance to score a big discount! Happy shopping! In this article Please note: price are correct and products in stock at time of publishing. We'll do our best to keep this story updated, but be aware products move fast during sales events. EDITOR'S PICKS: BEST DEALS OF THE WEEK Cotton On 50 per cent off the cosy edit Amazon Australia Esmi Shark Myer Ninja City Chic MCM House 30 per cent off all sofas, modulars and armchairs for a limited-time only DB Cosmetics Up to 70 per cent off sale The Oodie Shop the clearance sale – nothing over $49 30 per cent off sitewide Unreal Skin Clarks 40 per cent off everything Bae the Label Extra 20 per cent off sale Country Road Up to 50 per cent off selected styles Dyson eBay Unwritten Hair Get the best-selling Hydration Repair Trio, plus a free $89.95 Wooden Cushion Brush Emamaco Shop the epic outlet sale SmilePro Smilie Up to 50 per cent off sale $100 off Smilie Boost Teeth Whitening Kit, $119 (down from $219) Ergoflex Yinahla 15 per cent off mattresses Sleep Firm 15 per cent off mattresses Emma Sleep Up to 40 per cent off sale 40 per cent off the Emma Luxe Pro Mattress 25 per cent off the Emma Comfort Protect Mattress 10 per cent off the Emma Metal Bed BEST TRAVEL DEALS Monos $150 off luggage sets American Tourister Up to 50 per cent off sale July Bundle and save up to $125 off Samsonite 40 per cent off selected styles Strand Up to 40 per cent off sale BEST HOME DEALS Sheridan 30 per cent off bed linen Sheridan Outlet Up to 50 per cent off sale – members only Bed, Bath N' Table Nespresso 25 per cent off selected Original coffee machines 25 per cent off selected Vertuo coffee machines Sleeping Duck Save up to $200 off bundles Temple & Webster Up to 40 per cent off the warehouse sale Pillow Talk Our Place James Lane 20-50 per cent off when you buy two or more items Maison Balzac Shop the final sale Canningvale Up to 90 per cent off sale KitchenAid Up to 15 per cent off Sheet Society 20 per cent off selected styles BEST TECH DEALS Samsung The Good Guys Lenovo Up to 40 per cent off sale Vodafone Get 60GB for just $43/mth Bose Shop the winter sale JBL Up to 50 per cent off sale Sonos BEST FASHION DEALS Witchery Hype DC Up to 40 per cent off selected styles CAMILLA Extra 20 per cent off sale The Athlete's Foot Up to 40 per cent off sale Platypus Shoes Up to 40 per cent off sale Dr Martens Shop the Afterpay Day sale Van Heusen 40 per cent off sitewide Get three shirts for $119 Superdry 30-50 per cent off jackets Net-A-Porter Up to 60 per cent off sale Novo Shoes 25 per cent off almost everything Calvin Klein Viktoria & Woods Extra 30 per cent off sale Under Armour Spend and save up to 30 per cent off for Father's Day Lorna Jane 20 per cent off selected styles Adidas Shop the outlet sale Nike Up to 40 per cent off sale Tommy Hilfiger 30 per cent off menswear and kidswear Gorman 20-50 per cent off sale Princess Highway 20-60 per cent off sale Dangerfield 20-60 per cent off sale Coach Outlet 40 per cent off sitewide Oroton 40 per cent off sale, plus an extra 20 per cent off selected styles Christopher Esber Shop the end of season sale UGG Express Up to 80 per cent off sale Elka Collective Shop the end of season sale Stylerunner Extra 30 per cent off selected sale Betts 30 per cent off sitewide Le Specs BEST HEALTH AND BEAUTY DEALS the breakout hack Bundle and save up to 30 per cent off your order iHerb 20 per cent off sports 20 per cent off healthy habits Priceline Your Reformer SkinCeuticals 20 per cent off routine sets MAC Cosmetics 20 per cent off sitewide Sephora Up to 50 per cent off sale LELO Up to 40 per cent off sale Lovehoney Up to 70 per cent off sale Free gifts when you spend over $140 Shaver Shop Up to 80 per cent off sale Laser Clinics Australia 50 per cent off selected hair removal 40 per cent off AquaFacial Treatments Wild Secrets Up to 70 per cent off sale Sign up to our weekly shopping newsletter to get all the best deals, shopping tips and guides delivered straight to your inbox.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store